Travere Therapeutics, Inc. (TVTX)

Over the past six months, TVTX's stock price has been impacted by several events. The FDA review extension for FILSPARI in FSGS and the failure of the Phase 3 PROTECT trial led to a stock price decline. The company reported strong fourth quarter and full year 2025 financial results, leading to a stock increase. Multiple insiders, including CEO Eric M. Dube, engaged in substantial selling of company stock. Travere Therapeutics' stock has decreased by 24.2% since the start of the year.

Specific detailed information regarding the demand seasonality for Travere Therapeutics' products and services is not readily available. The company reported an "all-time high 908 new PSFs (patient start forms) received during the fourth quarter of 2025, driven by continued demand from new and repeat prescribers" for FILSPARI, suggesting consistent and growing demand rather than significant seasonal fluctuations.

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for individuals with rare kidney and metabolic diseases. The company's major products include FILSPARI for IgA Nephropathy and FSGS, Thiola and Thiola EC for cystinuria, Chenodal for radiolucent gallstones, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Pegtibatinase for classical homocystinuria.

Travere Therapeutics is headquartered in San Diego, California, and primarily operates in the United States. The company has expanded globally through collaboration agreements, with CSL Vifor launching FILSPARI in several European countries and Chugai Pharmaceutical planning to submit a New Drug Application for sparsentan in Japan in 2026.

Travere Therapeutics generally maintains a positive brand reputation within the analyst community, with a consensus rating of "Moderate Buy" or "Strong Buy". The FDA review extension and trial results have generated concerns, impacting sentiment. A law firm launched an investigation into Travere Therapeutics, Inc. The company's strong commercial execution and robust demand for FILSPARI in IgAN contribute positively to its reputation.

Travere Therapeutics' stock ownership is primarily institutional, with a significant individual insider holding. Key institutional shareholders include Janus Henderson Group Plc, Fmr Llc, BlackRock, Inc., Vanguard Group Inc, State Street Corp, Perceptive Advisors Llc, Delaware Management Holdings, Inc., Armistice Capital, Llc, Adage Capital Partners Gp, L.l.c., and Renaissance Technologies Llc. Ruth Shepley is the largest individual shareholder, owning 49.00 million shares, representing 53.12% of the company.